Diatrizoate

Brand names: Gastrografin · Active ingredient: Diatrizoate Meglumine, Diatrizoate Sodium

In short: Gastrografin (Diatrizoate Meglumine and Diatrizoate Sodium Solution) is indicated for radiographic examination of segments of the gastrointestinal tract (esophagus, stomach, proximal small intestine, and colon). The preparation is particularly indicated when a more viscous agent such as barium sulfa

LabelBracco Diagnostics Inc
Label updatedOct 13, 2021

What is Diatrizoate used for?

Gastrografin (Diatrizoate Meglumine and

Diatrizoate Sodium Solution) is indicated for radiographic examination

of segments of the gastrointestinal tract (esophagus, stomach, proximal

small intestine, and colon). The preparation is particularly indicated

when a more viscous agent such as barium sulfate, which is not water-soluble,

is not feasible or is potentially dangerous.

Gastrografin may also be used as an adjunct to contrast

enhancement in computed tomography of the torso (body imaging); the

preparation is indicated, in conjunction with intravenous administration

of a radiopaque contrast agent, when unenhanced imaging may not provide

sufficient definition in distinguishing normal loops of bowel from

adjacent organs or areas of suspected pathology.

âš  Boxed warning (FDA's strongest warning)

Dehydration: Administration of hypertonic

Gastrografin solutions may lead to hypovolemia and hypotension due

to fluid loss from the intestine. A 1 in 4.6 (1:4.6) dilution of Gastrografin

yields an approximately isotonic 16.5 percent diatrizoate salts solution;

less dilute solutions are hypertonic and may lead to intraluminal

movement of fluid with resulting hypovolemia. In young or debilitated

children and in elderly cachectic persons, the loss of plasma fluid

may be sufficient to cause a shock-like state. If Gastrografin is

used in infants and children (under 10 kg) or in dehydrated or debilitated

patients, the solution must be prepared using the specific dilutions

described in DOSAGE AND ADMINISTRATION. In

debilitated patients and in patients with electrolyte imbalances,

postprocedural monitoring of hydration, serum osmolarity, electrolytes

and clinical status is essential. In pediatric or severely debilitated

patients, the maintenance of an open intravenous fluid line for rehydration

may be advisable should hypotension or shock supervene. Electrolyte

disturbances must be corrected prior to the administration of any

hypertonic Gastrografin solutions.

Aspiration: Aspiration of Gastrografin into the trachea and airways

may result in serious pulmonary complications including, pulmonary

edema, pneumonitis or death Bronchial entry of any orally administered

contrast medium causes a copious osmotic effusion. Therefore, avoid

use of Gastrografin in patients with esophagotracheal fistula and

minimize risks for pulmonary aspiration in all patients. …

Diatrizoate dosage

This medium is not to be used for

the preparation of solutions for parenteral administration. Oral or

rectal administration only. Discard any unused portion after procedure.

The routine preparatory measures

employed for barium studies are also appropriate for this agent.

For pediatric and severely cachectic patients

the maintenance of an intravenous fluid line may be advisable.

Oral Administration: Adult oral dosage

may range from 30 to 90 mL (11 to 33 g iodine), depending on the nature

of the examination and the size of the patient. For infants and children

less than 5 years of age, 30 mL (11 g iodine) are usually adequate;

for children 5 to 10 years of age, the suggested dose is 60 mL (22

g iodine). These pediatric doses may be diluted 1:1, if desired, with

water, carbonated beverage, milk, or mineral oil. When used in infants,

the solution may be given in a nursing bottle. Pediatric doses may

also be used in dehydrated and/or debilitated adult patients. A 1:1

dilution is also recommended when the contrast medium is used in elderly

cachectic individuals.

For very

young (under 10 kg) and debilitated children the dose should be diluted:

1 part Gastrografin (Diatrizoate Meglumine and Diatrizoate Sodium

Solution) in 3 parts water is recommended.

For Enemas or Enterostomy Instillations: Gastrografin should be diluted when it is used for enemas and enterostomy

instillations. When used as an enema, the suggested dilution for adults

is 240 mL (88 g iodine) in 1,000 mL of tap water. For children under

5 years of age, a 1:5 dilution in tap water is suggested; for children

over 5 years of age, 90 mL (33 g iodine) in 500 mL of tap water is

a suitable dilution.

A usual adult dose is 240 mL of a dilute

Gastrografin solution prepared by diluting 25 mL (9.17 g iodine) to

one liter with tap water. Less dilute solutions [up to 77 mL (28.26

g iodine) diluted to one liter with tap water] may be used when indicated.

The dose is administered orally about 15 to 30 minutes prior to imaging

in order to permit the contrast medium to reach the pelvic loops.

Warnings & precautions

Do not take this medicine if: Do not administer to patients with a known

hypersensitivity to Gastrografin or any of its components.

Diagnostic procedures

which involve the use of radiopaque contrast agents should be carried

out under the direction of personnel with the prerequisite training

and with a thorough knowledge of the particular procedure to be performed.

Appropriate facilities should be available for coping with any complication

of administration, as well as for treatment of reaction to the contrast

medium .

Rectal administration

of undiluted Gastrografin (Diatrizoate Meglumine and Diatrizoate Sodium

Solution) in any patient, particularly with large doses and/or in

those with overdistention, has been reported to be associated with

mucosal irritation.

Cases of hyperthyroidism

have been reported with the use of oral contrast media. Some of these

patients reportedly had multinodular goiters which may have been responsible

for the increased hormone synthesis in response to excess iodine.

Administration of an intravascular iodinated radiopaque diagnostic

agent to a hyperthyroid patient precipitated thyroid storm; a similar

situation could follow administration of oral preparations of iodides.

Therefore, caution should be exercised when administering enteral

gastrointestinal radiopaque agents to hyperthyroid and euthyroid goiterous

patients.

Consideration should

be given to the potential for precipitation of water-soluble contrast

agents under conditions that may promote hyperacidity (i.e., fasting,

emotional upset, or stress). Harmful effects directly attributable

to precipitate formation have not been reported. However, the possibility

of interpreting the precipitate radiologically as an anatomical abnormality

(i.e., ulceration of the stomach or small intestine) or injury, should

be kept in mind. …

Diatrizoate side effects

Most adverse reactions to enteral diagnostic

radiopaque agents are mild and transitory. Nausea, vomiting and/or

diarrhea, urticaria with erythema, hypoxia, acute dyspnea, tachyarrhythmia,

and anaphylaxis have occurred following ingestion of the contrast

medium, particularly when high concentrations of large volumes of

solution are administered. Severe changes in serum osmolarity and

electrolyte concentrations may produce shock-like states . It should be kept in mind

that serious or anaphylactoid reactions that may occur with intravascular

administration of radiopaque contrast agents are theoretically possible

following administration by other routes.

About this medicine

Gastrografin (Diatrizoate Meglumine and Diatrizoate

Sodium Solution) is a palatable lemon-flavored water-soluble iodinated

radiopaque contrast medium for oral or rectal administration only.

Each mL contains 660 mg diatrizoate meglumine and 100 mg diatrizoate

sodium; pH has been adjusted to 6.0 to 7.6 with sodium hydroxide. Each mL contains approximately 4.8 mg (0.21 mEq) sodium and

367 mg organically bound iodine. Inactive ingredients: edetate disodium,

flavor, polysorbate 80, purified water, saccharin sodium, simethicone,

and sodium citrate.

Diatrizoate

meglumine is designated chemically as 1-deoxy-1-(methylamino)-D-glucitol

3,5-diacetamido-2,4,6-triiodo-benzoate (salt); diatrizoate sodium

is monosodium 3, 5-diacetamido-2,4,6-triiodobenzoate. Structural formulas:

How it works: The most important characteristic of contrast media is the iodine content. The relatively high atomic weight of iodine contributes sufficient radiodensity for radiographic contrast with surrounding tissues. Diagnostic enteral radiopaque agents have few known pharmacological effects.

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 8c2340e4-2b42-45dc-8fac-9960e8172547. Read the full official label on DailyMed.